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ABSTRACT
A COMPARATIVE STUDY ON THE EFFICACY OF
METHOTREXATE VS DAPSONE VS ASST (AUTOLOGOUS SERUM
SKIN THERAPY) FOR TREATMENT OF CHRONIC URTICARIA
INTRODUCTION
Chronic urticaria (CU) is a common skin disorder affecting 15–20% people
in the general population.Pathogenesis of CU is unclear and possible causes may
include chronic infections, allergy to certain food or food additives, anxiety, and
autoantibody production against IgE receptor. It remains a major problem in terms
of etiology, investigation, and management and causes comorbidity and high cost
to the health care system.
AIMS & OBJECTIVES
1. To compare the efficacy of treatment of dapsone, methotrexate and ASST
(Autologous Serum Skin Therapy) for chronic urticaria.
2. To determine the prevalence of auto immune urticaria in patients with
chronic urticaria.
3. To determine the remission rates for each treatment
4. To assess the improvement in UAS (Urticaria Activity Score) & DLQI
(Dermatology Life Quality Index) with treatment.
MATERIALS & METHODS
It is prospective and comparative study. Around 120 patients with chronic urticaria
were selected from the patients attending psoriasis out-patient clinic in Department of
Dermatology, Madras Medical College. All patients will be explained about the disease,
benefits & possible side effects of treatment. Informed written consent will be obtained
from all patients before initiation of treatment. The patients will be randomly allotted to
any one of the following four treatment groups after calculating their Urticarial Activity
Score (UAS) & Dermatology Life Quality Index (DLQI).Group A will comprise patients
who will be given oral Dapsone 50 mg for a period of 12 weeks.Group B will comprise
patients who will be given oral Methotrexate 10 mg per week for a period of 12 weeks.
Group C will comprise patients who will be given Treated with ASST (Autologous
Serum Skin Therapy) – 2ml of autologous serum deep intramuscular injection once a
week for 9 weeks.In addition to these, patients in all the groups will be prescribed
Antihistamines. Group D will be the control group who will receive only Antihistamines.
Patients were then divided into three categories based on their DLQI and UAS scores
intoGood Responders, Average Responders & Poor Responders.
RESULTS & DISCUSSION
The ASST group patients showed the maximal reduction in DLQI score
between baseline and the follow up value at six months with a drop of more than
ten points seen even in patients with poor response. ASST group patients also had
a high reduction inDLQI score soon after initiating treatment, with near complete
recovery seen as soon as completing treatment. In the dapsone group, the initial
response is lower than that of ASST and the net reduction is also lower than that of
ASST. The end points are comparable in each response group separately but is not
reliable as fewer patients showed good response. In methotrexate group, the initial
response was lower than both dapsone and ASST, with symptomatic improvement
becoming evident only towards the end of treatment or even after treatment. The
net reduction in DLQI score at the end of six months was similar to dapsone group.
There is a statistically significant difference in response to treatment to all three
groups when compared to control, with it being highly significant in the ASST
group. On comparing ASST with dapsone or methotrexate, there is again a
statistically significant difference in response while there was no statistically
significant difference when comparing dapsone and methotrexate.
CONCLUSION
1. Proper evaluation is mandatory to find out the presence of precipitating factor
and if present, management of the same
2. ASST can be considered as a first line of treatment, in patients with chronic
urticaria, especially in those who are positive for Autologous Serum Skin Test. The
preferred regimen being 2ml of autologous serum given as deep intramuscular
injections once a week for nine weeks
3. Dapsone can be considered for patients refractory to treatment. The regimen
being 50mg daily for a period of 12 weeks.
4. Methotrexate is recommended as last resort, in patients who are refractory to
other modalities of treatment. Side effects profile and its contraindication in
patients with haematological problems, restrict its more common usage
5. A randomized, controlled study with prolonged follow up and involving much
more modalities of treatment is necessary to devise an accepted management
protocol for patients with chronic urticaria.
INTRODUCTION 
Chronic urticaria (CU) is a common skin disorder affecting 15–20% people 
in the general population. Based on its duration, frequency and causes, CU can be 
classified into three clinical subgroups, spontaneous (80%), physical (10%) and 
special forms (10%). Chronic spontaneous urticaria (CSU), also known as chronic 
idiopathic urticaria, is characterized by spontaneous occurrence of wheals without 
an obvious stimulus lasting for more than 6 weeks. Pathogenesis of CSU is unclear 
and possible causes may include chronic infections, allergy to certain food or food 
additives, anxiety, and autoantibody production against IgE receptor. 
Ordinary chronic urticaria is appropriately termed as a “Cinderella” disease 
with a capricious course and a demoralizing response to treatments. There are no 
guaranteed means of controlling attacks. It can be difficult to determine the 
appropriate medication, as the condition is intermittent and outbreaks also typically 
clear up without any treatment. 
Chronic Urticaria remains a major problem in terms of etiology, 
investigation, and management and causes comorbidity and high cost to the health 
care system. In our study, we are comparing the use of ASST, Dapsone and 
Methotrexate for the treatment of resistant chronic urticaria. In addition, the clinio-
etiological patterns of the disease were ascertained. So, these study findings will 
play an important role to determine treatment protocols for patients with chronic 
urticaria 
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Review of Literature 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REVIEW OF LITERATURE 
2.1 Definitions 1,2 
 Urticaria is defined as a skin lesion consisting of a wheal-and-flare reaction 
where the localized intracutaneous edema (wheal) is surrounded by an area of 
redness (erythema) that is typically pruritic. Individual lesions last as briefly as 30 
minutes to as long as 36 hours. They can be as small as a millimeter or 6–8 inches 
in diameter (giant urticaria). They blanch with pressure as the dilated blood vessels 
are compressed, which  accounts for the central pallor of the wheal.  
Weals , also known as ‘nettle rash’ or  hives  is a transient, well-demarcated, 
superficial erythematous or pale swellings of the dermis, very itchy and are 
associated with a surrounding red flare. 
Angio-oedema also called as angioneurotic oedema is a swelling of the deeper 
dermis  subcutaneous and submucosal tissues. They are painful rather than itchy, 
poorly defined, and pale or normal in colour. 
Anaphylaxis, is an acute, severe, life-threatening, generalized or systemic 
hypersensitivity reaction. It consists of a combination of symptoms and signs, 
including diffuse erythema, pruritus, urticaria and angio-oedema, hypotension 
and difficulty in breathing.  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2.2 Historical Background 3-5 
 Urticaria, has a long and rich history.  Many cultures have described 
urticaria and the disorder has had many names. The earliest description of the 
disease is found in  “The Yellow Emperor’s Inner Classic”,by Huang Di Nei Jing, 
written  between 1000 BC and 200 BC . In 10th century B.C. it was called 'Feng 
Yin Zheng' in China. In  4th century B.C., Hippocrates noted similarities between 
urticaria,  stinging nettles, and insect bites and called the condition as 
'knidosis' (nettle rash). 'Uredo,' 'essera' (Arabic for elevation), 'urticatio' (derived 
from the Latin urere; to burn), and 'scarlatina urticaria' have all been used. 
 In 18th century, urticaria was compared with the stinging and burning of a 
nettle (Urtica dioica).  William Cullen was the first to use the term urticaria in 
1769. Many theories about the pathogenesis of urticaria have been described - a 
humoral theory , a metereologic theory in, and a menstrual theory in 1864.   
Different types of urticaria were described by willan and bateman: 
•Urticaria febrilis -  patient has fever and abdominal pain for some days before 
the skin lesions appear.  
•Urticaria evanida - new lesions can continue to appear for many months or 
years and mainly itching at night  
•Urticaria perstans - single central weal remains for some days and feels hard. 
The initial reddening around the weal disappears early. 
✓Cold urticaria - described by Frank in 1792. 
✓Solar urticaria - described by Borsch in 1799  
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✓Factitial urticaria -described by Heberden in 1767 and Gull coined the name 
factitious urticaria in 1859  
✓Angio-oedema -described 1586 by Marcello Donati  
✓Hereditary angio-oedema - Osler in 1885. 
✓Urticaria caused by heat and mental or physical exertion was published in 1924 
in by Duke. 
✓Pressure urticaria - described by Urbach and Fasal in 1929. 
✓Aquagenic urticaria - Shelley and Rawnsley in 1964  
✓Adrenergic urticaria - Shelley & Shelley in 1985. 
✓Urticaria pigmentosa - Edward Nettleship.  
✓Sangster named urticaria pigmentosa and Unna discovered the mast cells in the 
lesions. 
2.3 Epidemiology 6-8 
Urticaria affects 15%–20% of the population. Urticaria is a common problem, 
with a point prevalence of 0.1%. Lifetime prevalence of chronic urticaria varies 
from 0.05% to 23.6% in the general population, but a range of 1–5% seems more 
realistic. There is no racial variation in the incidence. Overall, urticaria is more 
common in women, with a female : male ratio of approximately 2:1 for chronic 
urticaria. Urticaria affects people of all age groups, but usually those in the second 
and  third  decade  of  life.  Hereditary  angioedema  has  an  autosomal  dominant 
inheritance pattern and occurs in approximately 1:150 000.
 6
An Indian study of 100 patients with urticaria found that 10% had urticaria due to 
bacterial infection; 69%, due to worm infestation; 6%, drug induced; 3%, insect 
bites; 2%, cold urticaria; 4%, cholinergic urticaria; and 3%, dermographism. 
Inhalants and food were responsible in 35% and 25% cases respectively. Among 
inhalants, 26% of cases were due to pollen; 9%, fungi; and 10% due to house dust 
and buffalo dander. In 6% of the cases, no cause could be detected. Among 500 
cases  of urticaria in another Indian study, 37% of the patients were suffering from 
physical urticaria, including 16.4% due to symptomatic dermographism; 10.8%, 
cholinergic urticaria; 8.4%, cold urticaria; 0.7%, solar urticaria; and 0.5%, both 
pressure and delayed cold urticaria. Hereditary angio-oedema, the 
autoinflammatory syndromes (cryopyrin-associated autoinflammatory syndrome) 
and a other rare physical urticarias are inherited as autosomal dominant traits. 
There is a highly significant linkage of human leukocyte antigen (HLA) DRB1*04 
(DR4) and its associated allele DQB1*0302 (DR8) with histamine-releasing 
autoantibody-positive chronic ordinary urticaria. Polymorphisms of the FcRI 
promoter and leukotriene C4 synthetase genes have been associated with aspirin-
sensitive urticaria. 
2.4 Histopathology 9-13 
 Edema is usually present in the superficial portion of the dermis in urticaria 
whereas it appears in the deeper dermis and subcutaneous tissue in angioedema. 
Dilated venules with endothelial swelling with minimal inflammatory cells are 
seen in acute urticaria, while a perivascular and interstitial infiltration of 
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lymphocytes, eosinophils and neutrophils is seen in chronic urticaria. In hereditary 
angioedema, only subcutaneous and submucosal edema is seen, but there are no 
inflammatory cells. 
 Immunoglobulin and complement proteins are not detected by direct 
immunofluorescence (DIF) tests. Major basic protein, a cytotoxic molecule from 
eosinophilic granules, is found in the dermis of skin lesions of chronic urticaria, 
delayed pressure urticaria, and solar urticaria. 
 An early leukocytoclastic vasculitic picture characterized by neutrophilic 
infiltration in and around dermal blood vessels, leukocytoclasis, minimal fibrin 
deposits and extravasation of erythrocytes is seen in urticarial vasculitis. DIF test 
showsprominent granular deposits of immune complexes along with 
dermoepidermal junction and perivascular areas. Positive immunofluorescence is 
seen more commonly in cases of urticarial vasculitis having a low complement 
level. Necrotizing vasculitis of venules has been found in dermographism, cold 
urticaria, pressure urticaria and solar urticria 
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FIG 1. Histopathological picture 
of urticarial lesion
2.5 Pathogenesis 14-20 
Pathomechanisms of different urticarias 
1. Mast cell-dependent urticarias: 
➢Immunologic: 
▪ Autoimmune urticaria (autoantibodies against FcRI or IgE) 
▪ IgE-dependent (allergic, mostly acute urticaria) 
▪ Contact urticaria (allergic, IgE-dependent) 
▪ Children with atopic dermatitis sensitized to environmental 
allergens like grass, animals and food 
▪ Glove-wearers having allergy to latex 
➢Non-immunologic: 
▪ Direct mast cell-releasing agents (e.g. opiates, vancomycin, 
polymyxin, some radiocontrast media, C5a, substance P, stem 
cell factor and some foods like strawberries) 
▪ Contact urticaria (nonallergic, certain histamine liberating 
chemicals that degranulate mast cells, e.g. dimethylsulfoxide 
and cobalt chloride) 
▪ Aspirin and other NSAIDs, dietary pseudoallergens 
2. Mast cell-independent urticarias: 
➢Immunologic: 
▪ Complement and kinin dependent (C1 esterase inhibitor 
   deficiency urticarias) 
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➢Non-immunologic: 
▪ ACE-inhibitors induced urticaria (believed to be from inhibition 
of endogenous kinase) 
▪ Contact urticaria (nonallergic, due to direct effect of urticants on 
blood vessels): 
▪ Sorbic acid and benzoic acid in eye solutions and foods 
▪ Cinnamic aldehyde in cosmetics 
▪ Histamine, acetylcholine and serotonin in nettle stings 
3. Urticarial vasculitis: 
 Type III hypersensitivity, cutaneous small vessel vasculitis with pronounced 
C5a-mediated mast cell degeneration 
4. Idiopathic: 
 Many forms of physical urticarias 
Basic Pathomechanism (Mast Cell Dependent) 
The Mast Cell 
The cutaneous mast cells have been implicated as major ‘effector’ cells which, on 
activation, liberate mediators, resulting in vasodilatation by increase in the local 
permeability of capillaries and venules. Both the phenotypes of mast cells (MCTC, 
mast cells of the skin and intestinal mucosa containing tryptase and chymase; and 
MCT, mast cells of the bowel mucosa, alveolar wall and nasal mucosa containing 
only tryptase) usually express high affinity IgE receptors (FcåRI) on their cell 
surface  and are able to take part in IgE-dependent allergic reactions. 
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Degranulation 
Initiation of degranulation of mast cells takes place on immunologic and non-
immunologic stimuli. Immunologic degranulating stimuli bring about: 
(a) binding of allergen to two adjacent receptor-bound specific IgE 
(b) binding of anti- IgE autoantibodies to receptor-bound IgE, and 
(c) binding of anti-FcRI autoantibodies directly to the subunits of the high affinity 
IgE receptor (FcRI).  
Non-immunologic stimuli cause mast cell degranulation by binding to the 
respective, specific cell surface receptors without involving FcRI. Degranulation 
usually takes place either by extrusion of entire granules outside the cell or by 
disintegration intracellularly. 
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Fig 2. Mast Cell Dependent Mechanism
  
Humoral Factors – Autoantibodies 
 Histamine-releasing functional IgE autoantibodies from mast cells and 
basophils and antibodies against the Fc portion of IgE may initiate complement 
activation with generation of C5a anaphylotoxin, further enhancing degranulation. 
Mediators 
 The mast cells contain both preformed mediators (histamine, heparin, 
proteases like tryptase, chymase) and newly formed mediators [leukotrienes C4, 
D4, E4 (LTC4, -D4, -E4), platelet activating factor and prostaglandin D2]. 
Cytokines [tumor necrosis factor (TNF-α), interleukins (IL-3, -4, -5, -6, -8, and 
-13) and granulocyte– macrophage-colony stimulating factor (GM-CSF)] have also 
been demonstrated in human mast cells. Histamine is the most important 
preformed mediator. On stimulation, H1 receptors in the skin induce itching, flare, 
erythema and wheal, but H2 receptors contribute only to erythema and wheal. 
However, wheal resolution is poorly understood. Chymase and tryptase help in the 
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Fig 3. Mast Cell Dependent Mechanism - - Degranulation
cleavage of C3 to C3a and C3b, which in turn activate mast cells and the 
alternative complement pathway respectively. Though convincing evidence of a 
significant role of PGD2 and LT4 in urticaria is lacking, they may contribute to the 
subsequent inflammatory events. PGE2 has been found to be an inhibitor of 
degranulation and thus may have a protective role in urticaria. Stimulation of  FcRI 
upregulates the synthesis and secretion of the cytokines mentioned above. Release 
of TNF-α induces expression of adhesion molecules, such as E-selectin, on the 
endothelial cells of post-capillary venules. 
Leukocytes 
Basophils are greatly reduced in the presence of histamine and releasing factors in 
serum and they release less histamine on anti-IgE stimulation. Expression of FcRI, 
release of histamine, IL-4, IL-13, and LTC4 are also seen on basophilic activation. 
Eosinophils play a role in the persistence of wheals by generating LTC4, LTD4 and 
LTE4 and by releasing major basic protein (MBP). Neutrophils and lymphocytes 
may also enhance and perpetuate the wheal response. 
Blood Vessels 
 Histamine and other mediators, bind to receptors on post-capillary venules, 
causing vasodilatation, edema and increase permeability to plasma proteins like 
albumin and immunoglobulin. The outcome of these events manifests clinically as 
a ‘wheal’. The expression of adhesion molecules on the endothelial cells of post-
capillary venules results in rolling of blood leukocyte and attachment to the 
endothelial luminal membrane. Blood leukocytes leave the circulation and enter 
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the cutaneous milieu. 
Other Pathomechanisms (Mast Cell Independent) 
 There are also other recognized patterns of urticaria where the mechanisms 
are not mast cell dependent. CI esterase inhibitor deficiency urticarias are, for 
example, complement and kinin dependent. Mast cell-independent urticarias again 
can be triggered by either immunologic or non-immunologic stimuli. The exact 
pathogenesis is not known in many patients (e.g. patients suffering from many 
physical urticarias). 
2.6 Clinical Classification 
Clinical classification of urticaria 21 
▪ Ordinary urticaria 
  Acute 
  Episodic (acute and chronic intermittent) 
  Chronic (previously qualified as ‘idiopathic’ prior to recognition of  
 the autoimmune subtype) 
▪ Physical and cholinergic urticarias 
▪ Urticarial vasculitis 
▪ Contact urticaria 
▪ Angio-oedema without weals 
▪ Other syndromes resembling urticaria or angio-oedema, or with urticaria as a 
component 
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‘Ordinary’ Urticaria  
 All urticarias can be grouped under ‘ordinary’ unless there is a 
predominantly physical trigger, histopathological evidence of vasculitis or a 
contact factor.  
Acute urticaria 22-26 
 
▪ Idiopathic 
▪ Infectious 
  Upper respiratory tract infection (NOS) 
  Streptococcal infection 
  Hepatitis B infection 
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Fig 4. Distribution of causative factors for acute urticaria
▪ Allergy (immediate hypersensitivity) 
  Foods 
  Drugs 
  (Inhalants) 
▪ Non-allergic 
  Histamine liberators (e.g. codeine, atracurium) 
  Pseudoallergens & Radiocontrast media 
Idiopathic 
 This form of acute urticaria, in which no cause can be identified, was found 
in more than 50% of patients with acute urticaria 
Allergic 
 Allergic urticaria due to drugs are common, usually occurring within 36 h of 
drug administration. Antibiotics, especially penicillins and cephalosporins, are 
common causes. Increased risk factors include previous exposure and reaction to 
the drug or a chemically related drug, intermittent and multiple drug therapy, and a 
familial predisposition. 
Acute urticarial reactions to food are believed to be common .Reactions typically 
occur within minutes and no more than 30 min. Stinging insects-  bees and wasps 
can also cause urticarial reaction. Allergic reactions to injected sting venom  are 
fatal. 
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 Non-allergic :  
 These may be due to direct histamine release from mast cells (histamine 
liberators) or due to other mechanisms (pseudoallergic). If they are very severe, 
resembling anaphylaxis, they are known as non-allergic anaphylaxis. Here, mast 
cell histamine release is not immunological and may occur after first exposure to a 
substance. Examples include morphine, codeine, atracurium and antibiotics, such 
as polymyxin and vancomycin. Iodine-based radiocontrast dyes may cause 
nonallergic anaphylaxis.  
Pseudoallergic reactions : 
 In these patients, a reaction occurs which is not specific for a particular 
substance, and the same reaction can occur other substances too in the same 
patient. How severe a reaction the patient experiences depends on the dose of the 
compound causing the reaction. 
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Fig 5. Causes of Allergic 
Urticaria
 NSAID’s and aspirin are among the frequently implicated drugs. These 
cause the reactions by pharmacological mechanisms thought to be related to their 
activity in inhibiting the cyclo-oxygenase (COX-1) pathway of arachidonic acid 
metabolism, diverting it to the pro-inflammatory lipoxygenase pathway products 
LTC4,D4,E4 and by reducing PGE2, which is inhibitory for immunological mast 
cell degranulation. 
 Alcoholic beverages can aggravate urticaria non-specifically. White wines 
are often treated with sulphites, which have rarely been reported to cause urticaria 
and anaphylaxis. Some red wines contain measurable concentrations of vasoactive 
amines including histamine which could aggravate urticaria. Food may also 
contain vasoactive amines including histamine (such as cheese, fish, meat, 
tomatoes, pineapple and avocados) or histamine-releasing substances (such as in 
strawberries). 
Infections : 
 Urticaria may follow non-specific viral infections, Epstein– Barr or acute 
hepatitis B viral infections, anisakiasis, streptococcal throat infections in children 
and Campylobacter jejuni. 
Inhalants : 
 Grass pollens, mould spores, animal danders and house dust mite have been 
implicated as triggers of acute or chronic urticaria. 
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Chronic urticaria 27-33 
 
Chronic urticaria is urticaria lasting more than 6 weeks’ duration  
✓ Idiopathic 
✓ Autoimmunity 
 Functional autoantibodies 
✓ Pseudoallergy 
  Salicylates 
  Food colours, preservatives, antioxidants and flavour enhancers 
✓ Infection 
  Bowel parasites 
  Helicobacter pylori 
  Candidiasis of the bowel 
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Fig 6. Distribution of causative factors for chronic urticaria
Idiopathic 
 It is still not possible to ascribe a specific aetiology to around 50% of 
patients presenting with the ordinary presentation of chronic urticaria. 
Autoimmune 
 Malmros in 1946 first observed an immediate wheal and flare response when 
the serum of some patients with urticaria was injected in to themselves. It is only 
over the last decade that the autoimmune basis of urticaria has been recognized 
based on the presence of histamine-releasing autoantibodies and their contribution 
to the pathogenesis of urticaria. About 40% cases of chronic urticaria have an 
autoimmune basis. There are circulating anti-IgE antibodies and also antibodies to 
the subunit of the high affinity IgE receptor (FcRI) located on the outer surface of 
all mast cells and basophils in 10% and 30% patients of chronic idiopathic urticaria 
respectively. These autoantibodies are IgG subtypes. In autoimmune urticaria, most 
autoantibodies are anti-FcRI and functional antibodies bind to FcRI in the presence 
of IgE but hardly in its absence. The IgG subtypes of autoimmune urticaria are 
IgG1 and IgG3 which can fix complement. Complement is a necessary cofactor 
and early components of the complement cascade are activated by binding of 
autoantibodies to antigens (FcRI or IgE). Histamine release is augmented by 
binding of C5a to complement receptors on mast cells or basophils. Anti-FcRI 
autoantibodies are also present in healthy nonallergic individuals in a non-
functional state. How these non- functional autoantibodies become pathogenic is 
explained by a hypothesis termed ‘conditional immunity’. Usually FcRI is 
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occupied by IgE and anti-FcRI cannot bind. A ‘change in receptor occupancy’ 
takes place when FcRI is not covered by IgE, facilitating anti-FcRI to bind to FcRI 
and become functional to release mediators. Thus, ‘conditional immunity’ as a 
unifying concept can explain the pathogenesis of urticaria by a disturbance in the 
receptor ligand equilibrium. Basophils have been found in a reduced number in the 
peripheral blood in autoimmune urticaria because of their recruitment in wheals. 
Mast cells, being primary effector cells, increase 10 folds in lesion. HLA-DR 
B1*04, HLA-DQB1*0301/4 and HLA-DQB1*03202 have been found in an 
increased frequency in autoimmune urticaria. However, severe continuous 
widespread wheals may be a clinical clue.  
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Fig 7. Various Mechanisms of Auto Immune Urticaria
Pseudoallergy  
 30% of chronic urticaria patients were considered to have intolerance 
reactions to dietary pseudoallergens as causing or aggravating their urticaria in a 
quality of life study. However, dietary additives and salicylates may be one of 
many factors that aggravate existing chronic urticaria  
Infections and infestations 
 Bacterial infections, such as dental sepsis, sinusitis, urinary tract and 
gallbladder infections also cause urticaria. H. pylori infection of the stomach has 
been associated with chronic urticaria. Protozoa or helminthic infection in the 
tissue may be a cause. Linear weals may follow migration of Ancylostoma and 
Strongyloides worms. 
Aggravating factors  
Aspirin and other non-steroidal anti-infl ammatories 
Dietary pseudoallergens 
Upper respiratory tract infections (NOS) 
Pressure 
Overheating 
Premenstrual period in women 
Alcohol 
Stress 
Unrelated viral infections 
Implants and nickel allergy 
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Physical Urticarias 34 - 55 
Physical and cholinergic urticarias 
 Here a specific physical stimulus induces reproducible wealing. Cholinergic 
urticaria occurs in response to sweating caused by an increase in core temperature. 
Wealing caused by physical stimuli  occurs within minutes and persists for less 
than 30–60 mins. 
A classification of physical urticarias  : 
❖ Due to mechanical force 
  Dermographism 
   Immediate 
    Symptomatic dermographism  
    Simple dermographism  
   Red dermographism  
   Cholinergic dermographism  
   Delayed dermographism  
   Associated with mastocytosis (Darier’s sign)  
  Delayed pressure urticaria  
  Vibratory angio-oedema  
❖ Due to heat 
  Generalized heating 
  Cholinergic urticaria   
   Variants 
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   Cholinergic pruritus  
   Persistent cholinergic erythema  
  Cholinergic dermographism  
   Exercise-induced anaphylaxis  
  Localized heating : Heat contact urticaria  
❖ Due to cold 
  Acquired 
   Primary (idiopathic) 
   Localized cooling 
    Cold erythema  
    Immediate cold contact urticaria  
    Delayed cold contact urticaria  
    Localized cold contact urticaria  
   Generalized 
    Generalized reflex cold urticaria  
    Cold-dependent cholinergic urticaria  
   Secondary (to serum cryoproteins)  
❖ Others 
  Solar urticaria 
  Aquagenic urticaria 
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Dermographism 
 This involves the triple response which may arise from firm stroking of the 
skin - local erythema due to capillary vasodilatation, followed by oedema and a 
surrounding flare due to axon reflex-induced dilatation of arterioles. There is rapid 
appearance of a linear wheal with flare at the site where a brisk and firm stroke is 
made with a firm object. Immediate dermographism is classified into two major 
forms: simple and symptomatic. Simple immediate dermographism is seen in 5% 
of normal people and may be considered as an exaggerated physiological response. 
Symptomatic dermographism is the commonest of the physical uricarias and the 
patients, most frequently young adults, complain of pruritus before the wheals 
appear. Its prevalence in chronic idiopathic urticaria is estimated to be 22%. 
Symptomatic dermographism is most easily diagnosed by using a calibrated 
instrument, the dermographometer.  
There are some special types of dermographism : 
1. Delayed dermographism 
2. Cholinergic dermographism 
3. Cold dependent dermographism 
4. Red dermographism 
5. White dermographism 
6. Black dermographism 
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Pressure Urticarias 
These may be immediate or delayed. 
Immediate Pressure Urticaria : Wheals occurs within minutes of applying 
perpendicular pressure to the skin. Urticaria persists for 30 minutes to a few hours. 
Delayed Pressure Urticaria : The swelling of delayed pressure urticaria (DPU) 
takes place within 30 minutes to 12 hours after pressure and is often pruritic and 
painful, and persists for 12 to 72 hours. Lesions appear at the site of tight clothing 
(like the waistline), on the hands after manual work, on the buttocks after sitting on 
hard surfaces, or on the soles after standing (especially on a ladder). The diagnosis 
of DPU: keeping standardized weights on defined areas for specified times and 
watching for a palpable wheal locally 2 to 8 hours later. 
Vibratory angio-oedema : Any vibratory stimulus such as jogging, vigorous 
towelling or using lawnmowers induces a localized, red, itchy swelling within 
minutes and lasting less than a few hours. 
Urticaria Due to Temperature Changes 
Cholinergic Urticaria : It is a type of urticaria characterized by the appearance of 
very small (1–2 mm) papules (micropapules) due to stimulation of sweating either 
by increased core temperature or by emotional stress. Sometimes, gustatory 
stimuli, such as peppery or sour foods, can precipitate an attack. The lesions first 
tend to appear over the neck and upper thorax. These areas appear flushed. 
Gradually other areas are involved and lesions become confluent, resembling 
angioedema. The lesions usually persist for a few minutes to an hour or two. 
 26
Occasionally, lacrimation, salivation and diarrhea are seen, indicating severe 
cholinergic stimulation. Systemic features like abdominal cramping, diarrhea or 
even fainting may be seen. Initiating typical wheals by warming [e.g. taking a hot 
bath (420C) for 15 minutes to raise the core temperature by 0.7–10C or simply 
asking the patient to exercise in a hot environment] is the best way to diagnose 
cholinergic urticaria. 
Localized Heat Urticaria : It is an extremely rare form of physical urticaria where 
wheals restricted to warmed areas usually start within 2 to 15 minutes of contact 
with heat and last for 1 to 3 hours  they may show a delayed appearance and 
disappearance of wheals, with even 10 hours required for complete resolution. The 
minimum temperature required to induce localized heat urticaria is 390C. Heated 
autologous serum at 400C, when injected, reproduces a similar eruptions. 
Adrenergic Urticaria (Stress Induced Urticaria) 
 This is  a rare type  in which multiple small wheals are induced by stress, but 
not by heat and exercise. It is differentiated clinically from cholinergic urticaria by 
the presence of blanching and vasoconstriction surrounding the wheals. It can be 
reproduced by intradermal injections of epinephrine and norepinephrine, but not by 
acetylcholine. 
Cold Urticarias 
 Cold urticarias represent a heterogeneous group of conditions in which cold 
exposure leads to wheals within minutes. They can be broadly divided into: 
(a) primary cold urticaria (96%), and (b) secondary cold urticaria (4%) 
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Exercise Induced Urticarias 
 In this type, exercise induces anaphylactic symptoms. It can occur without 
the typical wheals of cholinergic urticaria and is produced by exercise, but not by 
an increase in core temperature that usually provoke cholinergic urticaria.  The 
common precipitating exercises are jogging and active sports. Itching occurs first, 
followed by urticaria and  angioedema, which persist for 30 minutes to 4 hours 
Food and Exercise Induced Anaphylaxis 
 This is characterized by angioedema and/or anaphylaxis occurring within 
minutes of exercise if it follows either prior ingestion of a specific food (e.g. 
wheat) or sometimes within four hours of a heavy meal. Specific foods implicated 
are shellfish, wheat, vegetables  and fruits like grapes, apples, tomatoes and nuts.  
Solar Urticaria 
 It is a rare condition where itching, erythema and wheals appear rapidly 
within minutes in areas of sun exposure and disappear within an hour after 
exposure ceases. SU is broadly divided into primary solar urticaria (PSU), where 
no other factors that can secondarily sensitize to sunlight have been detected, and 
secondary solar urticaria (SSU). There are also special types of SU : 
 Primary Solar Urticaria 
 Secondary Solar Urticaria 
 Fixed Solar Urticaria 
 Delayed Solar Urticaria 
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Aquagenic Urticaria 
 Characterized by the eruption of small pruritic wheals surrounded by a flare 
on contact with water at any temperature. The wheal disappears within 30 to 60 
minutes after contact with water has ceased . All forms of water—tap, swimming 
pool, distilled water, high humidity, tears, sweat and saliva—induce whealing. The 
upper trunk and neck are usually affected in contrast to aquagenic pruritus where 
water-induced itching without wheals predominantly occurs on the legs and lower 
trunk.  
Contact Urticaria 
 It is an immediate urticarial reaction of a local wheal and flare that appears 
within minutes to an hour after contact with a provoking substance. Contact 
urticaria can be classified into two broad groups according to its pathomechanisms: 
1) non-immunologic contact urticaria (NICU), and (2) immunologic contact 
urticaria (ICU).  
Commonly encountered contactants causing nonimmunologic contact urticaria 
1. Foods: Fish, capsicum 
2. Fragrance and flavoring agents: Balsam of Peru, menthol, vanilla, cinnamon  
3. Drugs: Benzocaine, dimethyl sulfoxide, methyl salicylate, tar extracts, tincture 
of benzoin, capsaicin, camphor, chloroform 
4. Plants: Nettles, chrysanthemum 
5. Animals: Arthropods, caterpillars, moths 
6. Preservatives and germicidals: Benzoic acid, chlorocresol, formaldehyde 
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7. Others: Acetic acid, benzophenone, cobalt chloride, turpentine, sulfur 
Immunologic Contact Urticaria 
The reaction in ICU is well explained by a type I hypersensitivity reaction (IgE 
mediated) in a previously sensitized person. Cross sensitization is well 
documented; a patient sensitized to one protein can react to another protein due to 
the presence of a chemically related allergen in both the proteins.  
Commonly encountered contactants for immunologic contact urticaria 
1. Dairy foods: Milk, egg, cheese 
2. Fruits: Apple, banana, litchi, lime, mango, orange, watermelon, peanut 
3. Vegetables: Beans, carrot, cabbage, cucumber, garlic, onion, tomato, soybean 
4. Meat: Chicken, pork, lamb, beef  
5. Drugs: Aspirin, ampicillin, bacitracin, gentamicin, neomycin, rifamycin 
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Fig 8. Food substances causing urticaria
Urticarial Vasculitis 
 Urticarial vasculitis (UV) is characterized clinically by the presence of 
urticarial wheals lasting more than 24 hours and histopathologically by vasculitis 
in the form of vessel inflammation, perivascular hemorrhage, fibrinoid necrosis 
and leukocytoclasis. It is a type III hypersensitivity reaction. UV is more common 
among middle aged women, though it occurs unusually in children. 
Distinctive urticarial syndromes: 
❖ Systemic capillary leak syndrome /  Clarkson’s syndrome 
❖ Schnitzler’s syndrome / Urticarial vasculitis with monoclonal gammopathy 
❖ Cryopyrin-associated periodic syndrome / Muckle–Wells syndrome 
❖ Familial Mediterranean fever 
❖ Hyper-IgD syndrome  
❖ TNF-receptor-associated periodic syndrome (TRAPS) / Familial hibernian 
fever  
Urticaria in childhood : 
 Cow’s-milk allergy is the commonest cause of urticaria in infants. There is 
less itching and a greater tendency for weals to become purpuric. Acute 
haemorrhagic oedema of infancy (purpura en cocarde) occurs in very young 
children and is borderline between urticaria and vasculitis.  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Fig 9. Papular lesions seen in urticaria Fig 10. Urticarial Vasculitis
Fig 12. Cold UrticariaFig 11. Urticarial Rashes
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Fig 13. Cholinergic Urticaria
Fig 14. Aquagenic Urticaria
Fig 15. Dermographism
2.7  Clinical Features & Investigations
Clinical Features 56-58 : 
 Itchy, erythematous  pale to pink, oedematous, raised areas of the skin are 
present with a surrounding red flare. They occur anywhere on the body,in variable 
numbers and sizes, ranging from a few millimetres to large lesions,  of varying 
shapes including rounded, annular, serpiginous and bizarre patterns. Very rarely, 
bullae may form when oedema is intense. 
 Weals last a few hours and resolve within 24 hr leaving the skin with a 
normal  appearance. They are generally very itchy and Patients tend to rub rather 
than scratch, so excoriation marks are unusual, but occasionally bruising may 
result, which may be seen particularly on thighs. Weals may be more pronounced 
in the evenings or premenstrually. There may be associated angio-oedema in 50% 
of patients with ordinary urticaria. Urticaria may be associated with systemic 
symptoms of malaise, loss of concentration, low mood, feeling hot and cold, 
headache, abdominal pain or diarrhoea.
Investigations 59-64 :
Initial work up 
 History taking: 
✓ Time of onset (time of day, time of year) 
✓ Duration of urticaria (acute or chronic) 
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✓ Duration of individual lesion 
✓ Enquiry for food, food additives, drugs, infection 
✓ Enquiry for home and work environment 
✓ Family history of thyroid and other autoimmune diseases 
✓ History of atopy 
✓ History of dental diseases  
Physical examination: 
✓ Morphology of lesion (small papules, plaques, combination of 
lesions, thickness of lesions) 
✓ Distribution (localized, generalized, sun exposed skin, other 
sites) 
✓ Tests for physical urticarias (stroke, exercise, ice cube test) 
✓ Features of systemic involvement (fever, arthralgia) 
✓ Clinical evidence of any infection (dental caries, periodontal 
disease, sinusitis, cystitis, vaginitis) 
Laboratory work up and special tests 
Initial screening tests: 
 CBC, DC, ESR, platelet count 
 LFT 
 T4, TSH 
 Urinalysis 
 Stool for ova and parasites 
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Disease-specific focused tests: 
➢Autoimmune Urticaria : 
o Peripheral basophil count (to document basopenia by a sensitive assay) 
o Functional release assays with basophils and mast cells, and 
o Immunoassay. 
o Autologous Serum Skin Test (ASST) : The specificity of ASST is 
about 80%. About 50%–60% of cases of chronic idiopathic urticaria  
show a positive ASST, which is indicated by a red wheal with a 
diameter 1.5 mm greater than at the control site (saline injected site) at 
30 minutes  when  0.05 ml autologous serum is injected intradermally. 
The test is positive during disease activity and not during remission. 
ASST is usually negative in physical urticarias and healthy controls. 
➢Physical urticarias 
o Symptomatic dermographism: Dermographometer 
o Delayed pressure urticaria: By weighted rods modified from Illig 
➢Cholinergic urticaria 
o Provocation test by intradermal injection of methacholine 
➢Cold urticaria 
o Ice cube test, passive transfer of cold urticaria test, serum cryoprotein  
estimation. 
➢Food and exercise induced anaphylaxis FEIA 
o Prick test for specific IgE-dependent FEIA 
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➢Solar urticaria : Spectrodermograph, Solar simulator 
➢Aquagenic urticaria: Wet swab test at body temperature 
➢Contact urticaria: Open patch test, prick test, scratch test, use test, RAST 
➢Urticarial vasculitis: C3, CH50, Skin biopsy 
➢Angioedema (Hereditary): C4, C1 esterase inhibitor (functional) (Acquired): 
C4, C1q, C1 INH (quantitative, functional) 
➢Thyroid diseases : Thyroid antibodies 
➢Hepatic diseases : Hepatitis associated antigens and antibodies 
➢Collagen vascular diseases: ANA and other disease-specific tests 
➢Special tests : 
 X-ray of the chest, sinuses, and teeth 
 Oral challenge test (food additives) 
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2.8 Differential Diagnosis 
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2.9 Management 65-103 
General Measures : 
 Advice and information on common precipitants should be provided to 
patients. Aggravating factors hinted by history (e.g. stress, alcohol, cold exposure, 
and heat) and the different triggers for physical urticarias should be explained to 
them. Clear information and advice on preventive measures (e.g. covering exposed 
skin in cold urticaria, and a cooling shower for cholinergic urticaria) should be 
provided. Avoidance of aspirin and other NSAIDs, which aggravate chronic 
urticarial like calamine or 1% menthol in aqueous cream may help relieve pruritus. 
Acute Urticaria : 
 There should be an arduous attempt to identify the initiating stimulus. In 
most of the cases it is foods, drugs or infections. Its avoidance may help in 
controlling urticaria. Patients may require an oral H1 antihistamine and in resistant 
cases, an H2-antihistamine in addition. 
 If there is anaphylaxis, subcutaneous epinephrine injections with or without 
parenteral H1 and H2 antihistamines (e.g. 50 mg of diphenhydramine and 50 mg of 
ranitidine) should be given immediately. Systemic corticosteroids are sometimes 
useful. Measures for preventing airway obstruction, intravenous fluid replacement 
to combat shock and other supportive measures are to be taken as well. 
Pretreatment with an H1 antihistamine and corticosteroids is used in patients with 
an intravenous contrast media reaction and prophylactic use of  corticosteroids 
prior to surgery is advocated in latex allergy patients.  
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Chronic Urticaria : 
 The treatment of chronic urticaria (CU) include several drugs that have 
antiinflammatory or immunosuppressant effects. Therapy must be individualized. 
The decision to use a certain medication should be specific for the patient, taking 
into account concomitant medical conditions and patient preferences. 
 Antihistaminics and other commonly used agents, which have been proven 
to be effective in patients, can be contiued, while starting these more advanced 
treatment modalities. 
Terminology — 
●"Antiinflammatory" - -  includes agents which acts against the inflammatory 
cascade and has a favourable side effects profile but has less efficacy. Example - - 
dapsone, hydroxychloroquine and sulfasalazine. 
● "Immunosuppressant" - -  denotes a group of drugs that are known for their 
immune suppression properties but are let down by their increased prevalence of 
side effects. Example - -  calcineurin inhibitors and mycophenolate mofetil. 
First Line Therapies 
Antihistamines 
 H1 antihistamines are the cornerstone of pharmacologic therapy in all 
patients of chronic urticaria. They reduce pruritus, flatten wheals, and reduce wheal 
duration and number.  
 The third generation H1-antihistamines (desloratadine, fexofenadine) are 
preferred over the first generation ones to start treatment as monotherapy because 
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they are less sedating and have less cholinergic side effects. To get consistent 
results these drugs are to be taken on a regular basis and not as and when required. 
A drug of a different pharmacological class may be used to replace the initial drug 
if there is no response or added to the initial agent in case of a partial response. If 
non-sedating antihistamines fail and if addition proves to be more cost effective 
than escalating the dose of the non-sedating agent, then a sedating antihistamine 
(first or second generation,e.g. hydroxyzine, chlorpheniramine, cetirizine or 
mizolastine) at night is added. 
 The next step is to try a combination of H1 and H2 antihistamines. The 
significant wheal and flare suppression by co-administered hydroxyzine and 
cimetidine has been documented. Doxepin, a tricyclic antidepressant, has both H1 
and H2 antihistamine effects. It is effective in urticaria, with variable success rates. 
 As a general rule, antihistamines are safe and have few significant adverse 
effects. Chlorpheniramine is often selected for use in pregnancy because of its long 
safety record, but it is not licensed for this indication and is better avoided in the 
first trimester. 
Second and Third Line Therapies : 
These include the Anti – Inflammatory & Immunosupressant Agent along with 
alternative modalities like ASST and also non pharmacological therapies 
Antiinflammatory agents : 
The antiinflammatory agents that are best studied in chronic urticaria (CU) are 
dapsone, sulfasalazine, and hydroxychloroquine. 
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Dapsone : 
 Dapsone is a sulfone antimicrobial agent, well tolerated, easily available, 
and cost effective. In CU, dapsone acts by suppressing prostaglandin and 
leukotriene activity, interfering with release or function of neutrophil lysosomal 
enzymes, disrupting integrin-mediated neutrophil adhesiveness, inhibiting 
neutrophil recruitment and activation signals, and scavenging oxygen-free radical 
intermediates. Studies of dapsone for the treatment of CU include the following: 
 A case series of 11 CU patients, refractory to antihistamines alone, reported 
symptomatic improvement in 9 subjects within  weeks of low dose of dapsone (25 
mg daily). In the 2 remaining patients, the dose was titrated to 50 mg daily, which 
resulted in a complete response in 1 subject and partial response in the other. 7 
patients had remission lasting variable periods of time after stopping the drug.  
 Prior to initiating dapsone therapy, CBC and liver function tests have to be 
checked, because this agent is avoided in a patient with anemia or abnormal liver 
function. Dapsone can also cause severe hemolytic anemia in patients with G6PD 
deficiency 
 In adults, starting dose is 100 mg daily. In two weeks, CBC and liver 
function tests are repeated and repeat these monthly for three months, and then less 
often. The dose can be reduced once there is a clear clinical response. A four- to 
six-week trial is usually sufficient to determine effectiveness.  
 Peripheral neuropathy, clinically significant methemoglobinemia, 
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agranulocytosis, and drug allergic reactions, such as the drug rash with 
eosinophilia and systemic symptoms (DRESS) are rare, but serious reactions that 
warrant immediate discontinuation of dapsone  
 
 
Sulfasalazine : 
 Sulfasalazine is an antiinflammatory 5-aminosalicylic acid (5-ASA) 
derivative. Sulfasalazine is preferred for patients with underlying anemia, and 
therapy is initiated with the combination of sulfasalazine and hydroxychloroquine 
 Mechanisms of action include alteration of adenosine release, decreased 
leukotriene and prostaglandin synthesis, inhibition of immunoglobulin E (IgE)-
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Fig 16. Biochemical Structure of Dapsone
mediated mast cell degranulation, attenuation of neutrophil respiratory burst, and 
inhibition of early-phase events in the proliferation and differentiation of B 
lymphocytes 
 In adults, treatment is started with 500mg two times a day for a week and 
then can be titrated up to 1 gram twice a day. Side effects include nausea, 
headache, mild or transient leukopenia, and transaminitis. Laboratory monitoring 
with a CBC, liver function tests, and urinalysis is performed every month for the 
first three months, and then less often. A four- to six-week trial is usually sufficient 
to determine effectiveness 
Hydroxychloroquine : 
 Hydroxychloroquine is an antiinflammatory drug and antimalarial agent. It 
is a relatively safe and cheap drug. The major drawback is a comparatively slower 
onset of action. This can be dealt with by giving hydroxychloroquine in 
combination with dapsone or sulfasalazine. Mechanisms of action include 
suppression of T lymphocyte activation and disruption of antigen processing and 
other cellular processes by alkalinization of intracellular vacuoles in macrophages 
and other antigen presenting cells  
 In adults, initially with dose of 200 mg twice a day. The most common 
adverse reactions are related to the gastrointestinal tract (nausea), skin (various 
macular lesions), and central nervous system (headache).Ophthalmologic 
problems, include corneal deposits & retinopathy are rare but possible side effects. 
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Corticosteroids :  
 One large, retrospective study reports long-term remissions in about 50% of 
cases of chronic urticaria with oral prednisone given in a short course in doses of 
0.3-0.5 mg/kg. The prednisone was started at a dose of 25 mg/day for 3 days 
followed by a rapid tapering within 10 days. The remissions achieved resulted in 
disease control with only antihistamines at licensed doses. On administration of a 
second course of prednisone, the remission rate further improved.  
 However, systemic corticosteroids are associated with severe adverse effects 
on long-term treatment (glucose intolerance, hypertension, osteoporosis, 
gastrointestinal bleeding, and weight gain). Thus, oral corticosteroids are 
recommended for use only as short courses in the management of urticaria.  
 In another study from India, Oral Mini Pulse (OMP) therapy was used in a 
series of 10 patients of chronic urticaria. Over a period of 2 months, methyl 
prednisolone 16 mg tablets twice a week, on Saturday and Sunday, were given 
along with levocetirizine 5 mg tablet daily. A significant reduction in Mean 
Urticaria Activity Scores was observed in most patients, with only two patients 
reporting steroid-related side-effects. The OMP regimen may help to minimize 
side-effects of oral corticosteroid therapy. 
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Leukotriene Antagonists : 
 Many studies have reported the efficacy of anti LTs Montelukast and 
Zafirlukast in Chronic Urticaria (CU). They may be especially useful in urticaria 
induced by food additives and/or aspirin and other NSAIDs. Pacor et al. reported 
that the combination of antiLTs and non-sedating antihistamines gives added 
benefit only in urticaria elicited by a known factor (food additives, aspirin, and 
autoimmune urticaria). They further suggest that the combination offers no added 
benefit in cases of chronic idiopathic urticaria. Similarly Bagenstose et al. also 
reported an added benefit by addition of antiLTs to cetirizine only in cases of 
severe autoimmune urticaria (positive autologous serum skin test). On the basis of 
his findings with use of antiLTs in a series 12 patients of steroid-dependent chronic 
urticaria and in view of their good tolerability and low cost, Asero recommends 
that antiLTs should be tried in all patients with unremitting, steroid-dependent 
chronic urticaria before more challenging therapies are considered. A few studies 
in the literature have reported no benefit with antiLTs, including a study from India 
which reports no improvement of symptoms in chronic idiopathic urticaria patients 
with montelukast monotherapy.  
 However, a short trial with these agents may be recommended in all patients 
with refractory urticaria, before considering other therapeutic agents. Montelukast 
can be used in doses of 10 mg/day. 
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IMMUNOSUPPRESSANT AGENTS : 
 In patients who are steroid dependent and suffering from toxicity, 
immunosuppressants may be effective. Agents used in the treatment of chronic 
urticaria (CU) include cyclosporine, tacrolimus, sirolimus, and mycophenolate. 
Calcineurin inhibitors : 
 Calcineurin inhibitors have been recommended for the management of 
highly symptomatic patients by experts. These drugs act by interfering with the 
calcium-dependent release of & responsiveness to histamine, leukotriene C4, and 
other mediators in mast cells and other cell types. They also have anti T 
lymphocyte activity. Cyclosporine also disrupts tumor necrosis factor (TNF)-alpha 
activity and secondarily inhibit neutrophil accumulation.  
Cyclosporine : 
 Cyclosporine has a rapid onset (sometimes within days), a high degree of 
efficacy comparable with prednisone and long lasting remission. 
 Early studies described significant improvement with relatively high doses 
(5 to 6 mg per kg daily). Severe side effects are uncommon, but include 
hypertension and renal insufficiency.  
 Blood pressure, blood urea nitrogen, and creatinine should be monitored 
monthly and fasting lipids periodically. Serum levels may be followed to ensure 
that the dose is not excessive, although the optimal therapeutic level for CU has not 
been defined.  
 47
Tacrolimus : 
 Experience with the use of tacrolimus in CU is limited. In one case series, 19 
patients with severe CU were treated with low-dose tacrolimus. Two patients 
discontinued tacrolimus due to side effects. At 12 weeks, 71 percent (12 patients) 
had responded to a significant degree.  
Sirolimus : 
 Sirolimus (rapamycin) was reported to be effective in two of three patients 
in a case report. The patients had previously failed multiple alternative therapies 
including montelukast, dapsone, hydroxychloroquine, colchicine, olsalazine, and 
mycophenolate mofetil. Of note, sirolimus and the related agent everolimus have 
been implicated in causing isolated angioedema. 
Mycophenolate : 
 Mycophenolate acts as an antimetabolite selectively for lymphocytes and 
also impairs expression of adhesion molecules and secondary leukocyte 
migration.The most common problems are gastrointestinal symptoms and 
leukopenia.  
Choice of agent and dosing : With cyclosporine, tacrolimus, and sirolimus, a trial 
of one month is typically adequate to determine efficacy. Mycophenolate is slower 
to work and may require increasing the dose every two to four weeks to determine 
efficacy. Usual recommendations is to treat patients at a dose required for  control 
of urticaria for three months, then taper the dose over several months as tolerated.  
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Methotrexate : 
 Methotrexate is an anti-metabolite used in the treatment of many chronic 
inflammatory diseases. It competitively inhibits dihydrofolate reductase (DHFR), 
an enzyme that participates in the tetrahydrofolate synthesis. DHFR catalyses the 
conversion of dihydrofolate to the active tetrahydrofolate. For the treatment of CU 
multiple mechanisms appear to be involved including: the inhibition of enzymes 
involved in purine metabolism, leading to accumulation of adenosine; inhibition of 
T cell activation and suppression of intercellular adhesion molecule expression by 
T cells; selective down-regulation of B cells; increasing CD95 sensitivity of 
activated T cells; inhibition of methyltransferase activity, leading to (de)-activation 
of enzyme activity relevant to immune system function and inhibition of the 
binding of Interleukin 1 beta to its cell surface receptor 
 In a report  published in 2007, 3 out 4 selected cases of recalcitrant urticaria 
were controllable with only cetirizine after a 2 month course of Mtx (10 mg/week) 
given in divided doses every weekend, along with folic acid and cetirizine. 
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 Autologous Serum Skin Test : 
 A placebo-controlled trial by Staubach et al. in 2006 suggested that 
autologous serum skin test (ASST) positive chronic urticaria patients can benefit 
from autologous serum therapy.  
 A multicenter, prospective, open-label trial of autologous serum therapy in 
chronic urticaria patients from India showed its efficacy in a significant proportion 
of ASST-positive patients along with some ASST-negative patients as well. At least 
59.7% of ASST positive and 46% ASST-negative patients showed significant 
improvements in signs and symptoms after nine weekly autologous serum skin 
injections were given. This improvement was sustained for at least 3-4 months 
after the last injection.  
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Fig 17. Biochemical structure 
of Methotrexate
 However, a randomized, three arm study from Istanbul comparing 
autologous serum and autologous whole blood injections to placebo injections in 
88 patients of chronic urticaria could not establish a statistically significant 
difference in efficacy between the three methods although autohemotherapy 
resulted in a marked decrease in disease activity and improvement in quality of life 
scores in CU patients.  
 In another trial for autologous serum therapy from India, 20 ASST-positive 
patients were given weekly autologous serum injections (0.05 ml/kg/week) 
intramuscularly, and of those, 9 (45%) showed excellent response, while another 5 
(25%) showed satisfactory response to the therapy. 
 In view of its low cost and good safety profile, autologous serum therapy 
may be a good option in ASST-positive patients with refractory urticaria. 
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 Omalizumab : 
 Omalizumab, a monoclonal antibody directed against immunoglobulin E 
(IgE), is effective for chronic urticaria (CU) patients 12 years of age and older that 
is not controlled with H1 antihistamine therapy.   
Dosing : Two doses were approved for CU refractory to H1 antihistamines: 150 mg 
or 300 mg every four weeks. Based upon the studies reviewed above, it is 
reasonable to start omalizumab with a dose of 300 mg every four weeks, and if the 
response is adequate, taper to a lower dose (eg, 150 mg every four weeks) or less 
frequent injections (every six weeks). No specific laboratory monitoring is required 
for patients receiving omalizumab for CU 
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Fig 18. Autologous Serum Skin Test
Therapies with significant limitations : There are additional agents that can be 
useful in the management of chronic urticaria (CU), although each has limitations, 
including one or more of the following: 
●High cost combined with limited evidence of benefit (eg, immune globulin) 
●Limited evidence of benefit (eg, colchicine, methylxanthines, phototherapy) 
●The potential for serious adverse effects (eg, cyclophosphamide, antifibrinolytics, 
anticoagulants, androgens) 
●Inconvenience/intensive monitoring requirements (eg, plasmapheresis) 
Immune globulin  : 
 Immune globulin is an immunomodulatory agent that alters cell adhesion, 
immunoregulatory molecules, complement function, cytokine levels, autoantibody 
production, and anti-idiotypic networks. It can be administered intravenously 
(intravenous immune globulin [IVIG]) or subcutaneously (subcutaneous immune 
globulin [SCIG]) Adverse effects are generally predictable and manageable 
TNF-inhibitors :  
 Tumor necrosis factor (TNF)-alpha has been shown to be upregulated in the 
epidermis in lesional and nonlesional skin of CU patients, but not controls. TNF-
inhibitors, including etanercept, adalimumab, and infliximab, have been studied in 
the treatment of CU. Reports of effectiveness are limited. TNF-inhibitors have 
several adverse effects including injection-site or infusion-related reactions, 
infectious complications, and others  
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Colchicine : 
 Colchicine may act to relieve CU by suppressing leukotriene generation or 
by decreasing leukocyte adhesiveness and migration. The single available 
randomized-controlled trial evaluated 12 patients with delayed pressure urticaria, 
and failed to demonstrate any effect compared with placebo. 
Androgens : 
 Androgens, which are effective in the treatment of hereditary angioedema, 
have been studied in chronic idiopathic urticaria and angioedema. Short-term 
adverse effects were reported as "infrequent," with two patients having transient 
elevations in transaminases that normalized without treatment cessation. The long-
term adverse effects of androgens include hypercholesterolemia, hypertension, 
acne, mood disorders, and transaminitis, and monitoring is recommended.  
Cyclophosphamide : 
 Cyclophosphamide are suggested for chronic urticaria patients in patients 
who are found to be resistant to the other treatment modalities. Its role in 
autoimmune urticaria has been documented based on its activity on plasma cells. 
Cyclophosphamide use is limited by expense, inconvenience, need for monitoring, 
and risk of serious adverse effects like delayed secondary neoplasia and 
hemorrhagic cystitis. 
Antifibrinolytics and anticoagulants : 
 Anti fibrinolytic agents like tranexemic acid and apportion which were used 
to manage angioedema was tried for urticarial patients in the seventies. The basis 
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behind these trials was that the pathways for fibrinolysis and coagulation are 
similar and have common points. The anticoagulants like heparin, warfarin have 
also been reportedly studied for their purported use in urticaria. Inspite of these 
studies its use is not suggested because any benefits is outweighed by the risks 
associated with them. 
Nondrug therapies : 
Nondrug treatments that have been studied in CU include phototherapy and 
plasmapheresis. 
Phototherapy : 
 Phototherapy as a treatment modality for chronic urticaria was studied and 
the results pointed to their efficacy in the management of solar urtcaria and other 
types of physical urticarias. It acts by targeting the cells and inflammatory 
mediators in parts of the skin which are directly irradiated. Mast cell degranulation 
is also affected. Several types of phototherapy – PUVA, narrow band UV-B and 
UV-A have been shown to effective 
Plasmapheresis : 
 Plasmapheresis acts by removing proteins and other products of 
inflammation, which serve the function of immune modulation, from the blood 
system of the patient. Various studies showed either complete resolution or at the 
least improvement in symptoms. 
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Role of Dietary Restrictions : 
 Numerous food studies have demonstrated that about 35%–40% of children 
with moderate to severe eczema have food allergy, and  eliminating the causative 
food causes significant improvement in the severity and extent of eczema. But food 
allergy is rare in adult-onset eczema. 
Allergy to egg is the most common one. Other food products include milk, soy, 
wheat and peanuts. So , food allergy screening tests such as skin prick tests and 
radioallergosorbent tests should be performed in young infants . Food challenges 
are more accurate; reactions may be immediate or delayed. Care should always be 
taken with recommendations for dietary restriction in young infants. Adequate 
nutrition should be maintained, and consultation with a dietitian is needed. 
Role of Anti H.Pylori treatment in chronic urticaria : 
 The role of H. pylori infection in CU has long been investigated with 
controversial results. Several authors demonstrated that H. pylori eradication was 
associated with a remission of urticaria symptoms, suggesting the possible 
involvement of H. pylori in the pathogenesis of this disorder. After anti-H. pylori 
therapy, 80% CU patients positive for H. pylori experienced complete remission of 
urticarial symptoms. However, Shakouri et al. utilized the Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE) system to 
evaluate 10 trials on the effectiveness of H. pylori eradication on CU and found 
that the benefit of HP eradication in patients with CU is weak and conflicting. A 
study in Germany showed no evidence stating that eradication of H. pylori 
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improves the outcome in patients with CU. Another recent study even showed that 
CU can be triggered by eradication of H. pylori, but the pathogenetic mechanisms 
are far from being clear. 
Management of chronic urticaria in special populations : 
Children : 
Recent guidelines have strongly recommended use of modern second generation 
H1 antihistamines as first-line therapy for urticaria in children. In children, the 
same first-line treatment and weight adjusted up dosing is recommended as in 
adults.  
There is one report of a single open label trial on use of cyclosporine in children 
with CIU. Seven children, aged 9 to 16 yrs, were given cyclosporine 3 mg/kg/day 
in two divided doses, with monitoring of serum cyclosporine levels, BUN, serum 
creatinine, and blood pressure. All the patients had cessation of symptoms after 
about 1-4 weeks and maximum by 8 weeks. No adverse effects were recorded in 
these seven patients.  
Hepatic, renal disease : 
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Pregnancy and lactation : 
 There have been no reports of birth defects in women having used modern 
second-generation antihistamines during pregnancy. The latest guidelines suggest 
use of loratadine, cetirizine, and levocetirizine during pregnancy. These are also 
pregnancy category B. All antihistamines are secreted in breast milk and use of 
first-generation antihistamines is discouraged during lactation to avoid excessive 
sedation. A short course of oral corticosteroids may be considered during 
pregnancy in case of severe exacerbations of urticaria. Potential side effects 
include malformations, neonatal adrenal insufficiency, and low birth weight. Risk 
to benefit ratio must be assessed before administration. Although oral steroids are 
secreted in breast milk, they are generally considered to be safe during lactation.  
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Aims & Objectives  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AIM OF THE STUDY 
1.  To compare the efficacy of treatment of dapsone, methotrexate and ASST  
 (Autologous Serum Skin Therapy) for chronic urticaria. 
2. To determine the prevalence of auto immune urticaria in patients with   
 chronic urticaria. 
3. To determine the remission rates for each treatment 
4. To assess the improvement in UAS (Urticaria Activity Score) & DLQI  
 (Dermatology Life Quality Index) with treatment. 
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Materials and Methods 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MATERIALS AND METHODS
3.1 Type of study       :  Prospective, Observational & Comparative study 
3.2  Study   approval  : Prior to commencement of this study - Thesis &  
    Ethical Committee of  Madras Medical College and  
    Rajiv Gandhi Government General Hospital, Chennai  
    had approved the thesis protocol. 
3.3  Place of study      : Rajiv Gandhi Government General Hospital 
3.4  Period of study    : Duration starting from 01 Oct 2014 to 31 July  
    2015 
3.5  Sample size          : 120 cases 
3.6 Selection of patients: 
a) Inclusion criteria-  
a)  Patients with Chronic Urticaria defined as urticarial eruption of 
more than 6 weeks duration characterized by hives or wheals 
b) Age > 18 yrs 
c) Patient is resistant to treatment with anti histamines.  
 b) Exclusion criteria:  
1. Age < 18 yrs & > 60 yrs 
2. Physical urticaria / Urticaria secondary to an underlying medical 
condition 
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3. Any contraindication to the treatment modalities like pregnancy, breast 
feeding, women wanting to conceive or underlying medical condition 
4. Has taken any treatment other than anti histamines
3.7 Study procedure:
 Around 120 patients with chronic urticaria will be selected from the patients 
attending psoriasis out-patient clinic in Department of Dermatology, Madras 
Medical College. All patients will be explained about the disease, benefits & 
possible side effects of treatment. Informed written consent will be obtained from 
all patients before initiation of treatment. Detailed history will be obtained and 
patients will be evaluated as follows  
1) General  and systemic examination. 
2) Dermatological examination.  
3) Investigations namely complete hemogram, liver function tests, renal function 
tests autologous serum skin test and chest xray.  
4) ENT & Dental opinion will be sought to rule out focal sepsis 
The patients will be randomly allotted to any one of the following four treatment 
groups after calculating their Urticarial Activity Score (UAS) & Dermatology Life 
Quality Index (DLQI). 
Group A will comprise patients who will be given oral Dapsone 50 mg for a period 
of 12 weeks. 
Group B will comprise patients who will be given oral Methotrexate 10 mg (in 4 
divided doses at 12 hourly interval) per week for a period of 12 weeks.  
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Group C will comprise patients who will be given Treated with ASST (Autologous 
Serum Skin Therapy) – 2ml of autologous serum deep intramuscular injection once 
a week for 9 weeks. 
In addition to these, patients in all the groups will be prescribed Antihistamines.  
Group D will be the control group who will receive only Antihistamines. 
3.8 Follow Up Assesment : 
SCREENING PROCEDURES / VISITS:  Patients will be reviewed every 4 weeks 
at 4,8 &12 weeks for complaints and assessing clinical improvement till 
completion of treatment and once every two months for six months following 
completion 
ASSESSMENT OF PARAMETERS: Blood parameters will be repeated every four 
weeks or as and when required and Parameters like Urticarial Activity Score(UAS) 
and Dermatology Life Quality Index(DLQI) will be assessed at end of treatment 
and at end of six months following treatment. 
Patients were then divided into three categories based on these parameters into 
Good Responders, Average Responders & Poor Responders. 
Good Responders :  Patients post treatment UAS score < 2 and DLQI score < 2 
Average Responders :Patients post treatment UAS score 2 - 4 & DLQI score 2 - 9 
Poor Responders : Patients post treatment UAS score > 4 and DLQI score > 10 
The higher of the two scores is taken into consideration while classifying the 
groups. 
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3.9 Variables studied: 
Dependent variable: UAS & DLQI score 
Independent variables: 
i)Age 
ii)Sex 
iii)Symptoms 
iv)Co-morbidities: COPD, jaundice, diabetes, obesity and malnutrition. 
v)Dermatological Examination
vi)ENT & Dental Examination
vii) Blood Investigations 
viii)ASST & Chest Xray 
3.10  Ethical consideration 
 All the patients/ legal guardians were given an explanation of the study and 
about the investigative and operative procedures with their merits and demerits, 
expected results, and possible complications. If he/she agreed then the case had 
been selected for this study. The study did not involve any additional investigation 
or any significant risk. It did not cause economic burden to the patients. The study 
was approved by the institutional review board prior to commencement of data 
collection.  Informed  consent  was  taken  from each  patient/guardian.  Data  were 
collected by approved data collection form. 
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3.11 Data collection 
Data were collected by pre-tested structured questionnaire. Data were collected 
from  all  the  respondents  by  direct  interview  after  getting  informed  written 
consent from them or from their legal guardian. 
3.12 Data analysis 
Data analysis was done both manually and by using computer. Calculated data 
were arranged in systemic manner, presented in various table and figures and 
statistical analysis was made to evaluate the objectives of this study with the help 
of Statistical Package for Social Science (SPSS). 
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RESULTS 
This prospective, observational, comparative study was carried out to determine 
the favourable  treatment  modality  for  patients  suffering from chronic  urticaria. 
One hundred and twenty patients with chronic urticaria were selected purposively 
from Department of Dermatology of Madras Medical College and Rajiv Gandhi 
Government General Hospital  during the period of 1 October 2014 to 31 July 
2015. All cases were evaluated clinically and essential investigations necessary for 
diagnosis were carried out. Patients initial UAS and DLQI score were calculated 
and recorded. Patients were then randomly divided into four groups and started on 
treatment  with  ASST,  Dapsone,  Methotrexate  and  Anti-histaminics.   Patients 
response to treatment was followed up with UAS and DLQI score at three and six 
months of treatment.  Based on the assessment of these scores,  the response to 
treatment was categorised into Good, Average and Poor. All data were collected 
and analysed and results derived. 
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TABLE  1  : Age & Sex Distribution of Patients with Chronic Urticaria 
 It was observed that age of 120 patients ranged from 18-56 years. Most of 
the  patients  (55.83  %)  were  in  between  18-29  years.  Females  were  the 
predominantly involved sex with male to female ration of 1 : 2.3 
Age / Sex Male Female Total
18 - 29 20 (16.67) 47 (39.17) 67 (55.83)
30 - 39 6 (5) 27 (22.5) 33 (27.5)
40 - 49 3 (2.5) 11 (9.17) 14 (11.67)
50 - 59 6 (5) 0 (0) 6 (5)
Total 35 (29.17) 85 (70.83) 120 (100)
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Table II :  Distribution of patients on the basis of duration
  
Chronic Urticaria denotes a duration of more than 6 weeks. In our study, majority 
of the patients presented around 3 to 9 months, constituting nearly 75% of the total 
number of cases. Only two patients presented with more than a year duration. 
Duration No. Of Patients Percentage
<  3 months 12 10
3 - 6 months 48 40
6 - 9 months 41 34.17
9 - 12 months 17 14.17
> 12 months 2 1.67
Total 120 100
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Table III: Prevalence of precipitating factors in chronic urticaria patient
 
Regarding precipitating factors, food allergens were the most common 
precipitating factor accounting for 15% of the cases, followed by infections & 
inhalants like house dust seen in 10% of cases. The other precipitating factors 
were drugs and water related. 65 % of the total patients had no specific 
aggravating or trigger factor for occurrence of symptoms. 
Precipitating Factor No. of Patients Percentage
Food 18 15
Infections 12 10
Inhalant 12 10
Drugs 8 6.67
Aquagenic 4 3.33
No Specific Factor 66 55
Total 120 100
 71
Food
Infections
Inhalant
Drugs
Aqua
NSF
0 17.5 35 52.5 70
Precipitaing Factor
Table IV:  Distribution of atopy in chronic urticaria patients 
 
 Around 26 patients (21.67%) had history or features suggestive of atopy. 
TableV: Distribution of co-morbid factors in chronic urticaria patients 
 Out of the 120 patients, 25 patients had co-existent systemic problems like 
diabetes mellitus seen in 9 (7.5%) patients, systemic hypertension in 4 (3.3%) 
patients and both hypertension and diabetes in 4 (3.3%) patients. Twenty one 
(17.5%) of these patients also had previously detected hypothyroidism. 
Atopy No. of Patients Percentage
Positive 26 21.67
Negative 94 78.33
Total 120 100
Co - Morbid Factor No. of Patients Percentage
Diabetes Mellitus 9 7.5
Systemic Hypertension 4 3.33
DM & HTN 4 3.33
BA 12 10
Hypothyroid 21 17.5
No Comorbidity 70 58.33
Total 120 100
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Table VI : Prevalence of ASST in chronic urticaria patients 
 
* Figures given in parentheses are percentage value 
Out of 120 patients in the study, 44 patients (36.67%) turned out to be positive for 
Autologous Serum Skin Test. Of these 37 patients (30.83%) were females and only 
7 patients (5.83%) were males. 
Positive Negative
Male Female Male Female
ASST 7 (5.83) 37 (30.83) 28 (23.33) 48 (40)
Total 44 (36.67) 76 (63.33)
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Table VII: Age and Sex Distribution based on the treatment offered
 120 patients were divided into four groups of 30 patients each and started on 
respective treatment regimen. In ASST group, there were 7 males and 23 females. 
In methotrexate group, there were 10 male patients and 20 female patients. In 
dapsone group, there were nine male patients and twenty one female patients. In 
control group, there were nine male patients and twenty one female patients 
Age ASST Methotrexate Dapsone Control
Male Female Male Female Male Female Male Female
18 - 29 5 12 5 9 7 12 3 14
30 - 39 1 8 1 7 1 8 3 4
40 - 49 - 3 1 4 1 1 1 3
50 - 59 1 - 3 - - - 2 -
7 23 10 20 9 21 9 21
Total 30 30 30 30
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Table VIII:  Distribution of response to treatment of all four groups of 
patients 
 
* Figures given in parentheses are percentages 
More than 73% of patients treated with ASST had good response to treatment 
while only 50% of those treated with dapsone and 33% of those treated with 
methotrexate had good response to treatment. Poor response was seen in 6% of 
ASST and Dapsone patients compared to the 20% in patients receiving 
Methotrexate. This is still better than the 53% with poor response in the control 
group. 
Good Average Poor Total
ASST 22 (73.33) 6 (20) 2 (6.67) 30
Methotrexate 10 (33.33) 14 (46.67) 6 (20) 30
Dapsone 15 (50) 13 (43.33) 2 (6.67) 30
Control 4 (13.33) 10 (33.33) 16 (53.33) 30
Total 51 (42.5) 43 (35.83) 26 (21.67) 120
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Table IX: Age & Sex Distribution of Patients with Good response to 
treatment 
 
* Figures in parentheses indicate the total number of patients in that subset 
 
Age ASST Methotrexate Dapsone Control
Male Female Male Female Male Female Male Female
18 - 29 3 (5) 10 (12) 0 (5) 3 (9) 5 (7) 4 (12)  0 (3) 3 (14)
30 - 39 1 (1) 6 (8) 0 (1) 4 (7) 0 (1) 6 (8)  0 (3) 1(4)
40 - 49 - 2 (3) 0 (1) 0 (4) 0 (1) 0 (1) 0 (1)  0 (3)
50 - 59 0 (1) - 3 (3) - - - 0 (2) -
4 (7) 18 (23) 3 (10) 7 (20) 5 (9) 10 (21) 0 (9) 4 (21)
Total 22 (30) 10 (30) 15 (30) 4 (30)
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Table X: Age & Sex Distribution of Patients with Average response to 
treatment 
* Figures in parentheses indicate the total number of patients in that subset 
 
Age ASST Methotrexate Dapsone Control
Male Female Male Female Male Female Male Female
18 - 29 2 (5) 2 (12) 3 (5) 4 (9) 2 (7) 7 (12)  1 (3) 5 (14)
30 - 39 0 (1) 2 (8) 1 (1) 3 (7) 1 (1) 1 (8)  2 (3) 0 (4)
40 - 49 - 0 (3) 0 (1) 3 (4) 1 (1) 1 (1) 1 (1)  1 (3)
50 - 59 0 (1) - 0 (3) - - - 0 (2) -
2 (7) 4 (23) 4 (10) 10 (20) 4 (9) 9 (21) 4 (9) 6 (21)
Total 6 (30) 14 (30) 13 (30) 10 (30)
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Table XI: Age & Sex Distribution of Patients with Poor response to 
treatment 
* Figures in parentheses indicate the total number of patients in that subset 
 
Age ASST Methotrexate Dapsone Control
Male Female Male Female Male Female Male Female
18 - 29 0 (5) 0 (12) 2 (5) 2 (9) 0 (7) 1 (12)  2 (3) 6 (14)
30 - 39 0 (1) 0 (8) 0 (1) 0 (7) 0 (1) 1 (8)  1 (3) 3 (4)
40 - 49 - 1 (3) 1 (1) 1 (4) 0 (1) 0 (1) 0 (1)  2 (3)
50 - 59 1 (1) - 0 (3) - - - 2 (2) -
1 (7) 1 (23) 3 (10) 3 (20) 0 (9) 2 (21) 5 (9) 11 (21)
Total 2 (30) 6 (30) 2 (30) 16 (30)
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Table XII:  Response to treatment in ASST positive patients 
* Figures in parentheses indicate the percentages 
 ASST positive patients generally had a good response to treatment with poor 
response seen in only five patients (11%) across all groups, with four of those 
patients being in the control group. Nearly eighty percent of the patients in the 
ASST treatment group had good response to treatment. 
 
Good Average Poor Total
ASST 11 (78.57) 3 (21.43) 0 14
Methotrexate 5 (50) 4 (40) 1 (10) 10
Dapsone 4 (50) 4 (50) 0 8
Control 2 (16.67) 6 (50) 4 (33.33) 12
Total 22 (50) 17 (38.64) 5 (11.36) 44
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Table XIII  :  Average DLQI score of patients in different treatment groups 
 
ASST Methotrexate Dapsone Control
Mon
ths
Good Aver
age
Poor Good Aver
age
Poor Good Aver
age
Poor Good Aver
age
Poor
0 10 18 22 8 13 19 9 12 18 6 11 17
3 3 8 15 5 8 14 3 8 12 4 9 14
6 1 5 8 2 6 12 1 5 10 3 6 12
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The mean DLQI score across all the treatment groups when compared 
showed that, patients treated with ASST had the fastest and the maximal 
response. Both the initial response and the end point was better in ASST 
patients. Control group patients showed no significant improvement in 
DLQI score. The dapsone and methotrexate treated patients had similar 
response profile but there was a difference in the number of patients 
responding.
TABLE  XIV  :  Shows P values of Response to treatment comparing two 
groups 
This table shows P values by comparing the four groups with one another. There is 
a statistically significant difference in response to treatment to all three groups 
when compared to control, with it being highly significant in the ASST group. On 
comparing ASST with dapsone or methotrexate, there is again a statistically 
significant difference in response while there was no statistically significant 
difference when comparing dapsone and methotrexate.  
Groups compared P - Values
ASST vs Control 0.001
Dapsone Vs Control 0.014
Methotrexate vs Control 0.022
ASST vs Dapsone 0.035
ASST vs Methotrexate 0.030
Dapsone vs Methotrexate 0.184
 83
TABLE XV  :  Prevalence of side effects in each treatment group 
 Side effects were more common in patients taking methotrexate with four 
out of thirty patients experiencing minor side effects while two patients taking 
dapsone also had documented side effects.  
No. of Patients Total patients 
treated
Percentage
ASST 0 30 0
Methotrexate 4 30 13.33
Dapsone 2 30 6.67
Control 0 30 0
Total 6 120 5
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DISCUSSION
 This  prospective,  observational  and  comparative  study  was  conducted 
among 120 purposively selected patients with chronic urticaria presenting to the 
Department  of  Dermatology,  Madras  Medical  College  and  Rajiv  Gandhi 
Government General Hospital. The study was carried out with a view to determine 
the factors responsible for chronic urticaria and to compare the efficacy of ASST, 
Dapsone  and  Methotrexate  as  treatment  modalities  for  patients  with  chronic 
urticaria. They were compared against a control group of patients treated with anti-
histaminic alone. 
Age of 120 patients ranged from 18-56 years.  Most of the patients (100, 
83.33 %) were in between 18-39 years; with mean age 30.51 years and standard 
deviation 3.81 years. Eighty five patients were females (70.83%) and thirty five 
patients were males (29.17%).  
Out of 120 patients, forty eight patients (40%) presented within three to six 
months  of  onset  of  symptoms,  while  forty  one  patients  (34.17%)  presented 
between six to nine months of onset. Twelve patients (10%) presented between six 
weeks to three months while seventeen patients (14.17%) presented between nine 
to twelve months. Two patients (1.67%) presented more than a year after onset of 
treatment.  All  these  patients  had  not  received  any  treatment  apart  from 
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antihistaminics during that period.  
An analysis of the common precipitating factors in these patients showed 
that allergy to food is the more prevalent factor seen in eighteen patients (15%). 
ENT and Dental infections was seen in twelve patients (10%). Allergy to inhalants 
like  house  dust,  pollen  etc  was  seen  in  twelve  patients  (10%).  Drugs  was  the 
precipitating  factor  in  eight  patients  (6.67%).  Sixty  six  patients  (55%)  had  no 
specific precipitating or aggravating factor.
Atopy  is  syndrome  characterised  by  a  tendency  to  be  “hyperallergic”. 
Naturally these people have a predisposition to develop chronic urticaria. In our 
study, twenty six patients (21.67%) had features of atopy.
Hypothyroidism  is  a  commonly  encountered  coexisting  disease  seen  in 
patients  with  chronic  urticaria.  A  possible  auto  immune  mechanism  being  a 
causative factor for both these diseases has been hypothesised. In our study twenty 
one patients (17.5%) had hypothyroidism. Bronchial asthma, an indicator of atopy, 
was seen in  twelve patients  (10%).  Other  systemic comorbidities  like  Diabetes 
Mellitus was seen in nine patients (7.5%), Systemic Hypertension in four patients 
(3.3%) and both in another four patients (3.3%)  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Autologous  Serum  Skin  Test  was  done  to  all  the  patients  in  the  study. 
Around forty four of the 120 patients were positive for ASST (36.67%). There was 
difference  in  gender  among  the  ASST  positive  patients.  Only  seven  patients 
(5.83%)  were  males  while  the  remaining  thirty  seven  patients  (30.83%)  were 
females. Seventy six patients (63.33%) were negative for ASST.
The  120 patients in the study were divided into four groups of 30 patients 
each and started on respective treatment regimen. In ASST group, there were 7 
male patients and 23 female patients. In methotrexate group, there were 10 male 
patients and 20 female patients. In dapsone group, there were 9 male patients and 
21 female patients. In control group, there were 9 male patients and 21 female 
patients.  The patients were divided in such a way that similar number of patients 
from each age set were included in each group. An average of fifteen patients in 18 
- 29 age group, nine patients in 30 - 39 age group, four patients in 40 - 49 age 
group and two patients in 50 - 59 age group were present in each treatment group. 
 The response to treatment was analysed in all the treatment groups based on 
reduction in the DLQI score and UAS score and symptomatic improvement. The 
response was then graded as good, average and poor.  
 Among the thirty patients treated with ASST, twenty two patients (73.33%) 
had good response to treatment, with six patients (20%) showing average response 
and only two patients (6.67%) showed poor response to treatment. 
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 Of the thirty patients managed with dapsone, fifteen patients (50%) showed 
good response to treatment. Thirteen patients (43.33%) showed average response 
to treatment with dapsone while two patients (6.67%) showed poor response. 
In patients treated with methotrexate group, ten patients (33.33%) showed 
good response to treatment, fourteen patients (46.67%) showed average response 
to treatment while six patients (20%) had poor response to treatment.
Comparing this  with the control  group,  around sixteen patients  (53.33%) 
showed poor  response to  treatment,  with  ten patients  (33.33%) having average 
response and only four patients (13.33%) had improvement in their symptoms.
ASST compared favourably to the other two drugs with nearly three fourths 
of the patients having significant symptomatic improvement while only fifty and 
thirty three percent of patients of the dapsone and methotrexate group had a good 
response to treatment. 
Both the methotrexate and dapsone group patients showed a better response 
to treatment than the control group with only two patients in the dapsone group and 
six patients  in  the methotrexate  group showing poor  response compared to  the 
sixteen patients in the control group. Both the methotrexate and dapsone group 
patients had similar number showing average response to treatment. 
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With regards to relation of age and sex to response to treatment, females had 
a slightly improved tendency to respond to treatment, but this was not significant. 
The increased numbers can be attributed to the generally more prevalence among 
the  female  sex.  Similarly,  age  seemed  to  have  no  effect  on  the  response  to 
treatment, with patients across all age groups showing same pattern of response in 
all the four treatment groups. 
ASST positivity has a significant relation with better response to treatment. 
ASST positive patients generally had a good response to treatment with poor 
response seen in only five patients (11%) across all  groups,  with four of those 
patients being in the control group. Nearly eighty percent of the patients in the 
ASST treatment group had good response to treatment, while fifty percent of the 
patients in the methotrexate and dapsone group showed good response. The above 
findings showed that treatment with autologous skin serum for patients who are 
ASST positive is the best option.  
An analysis of the DLQI scores, showed that patients having a mean DLQI 
score in the lower range generally had a good response to treatment. The ASST 
group patients showed the maximal reduction in DLQI score between baseline and 
the follow up value at six months with a drop of more than ten points seen even in 
patients  with poor response.  ASST group patients  also had a high reduction in 
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DLQI score soon after initiating treatment, with near complete recovery seen as 
soon as completing treatment.
In the dapsone group, the initial response is lower than that of ASST and the 
net reduction is also lower than that of ASST. The end points are comparable in 
each response group separately but is not reliable as fewer patients showed good 
response.
In methotrexate group, the initial response was lower than both dapsone and 
ASST, with symptomatic improvement becoming evident only towards the end of 
treatment or even after treatment. The net reduction in DLQI score at the end of six 
months was similar to dapsone group.
None of these patients surprisingly showed any signs of relapse. All the three 
treatment  groups  patient  showed  at  the  least  a  partial  response  with  definite 
reduction in symptomatology after starting treatment.
Four patients (13.33%) treated with methotrexate had side effects while two 
patients  (6.67%) who took dapsone had side effects.  None of  the ASST group 
patients had any side effects.  
 91
LIMITATIONS OF STUDY 
  
 As this  study has  been carried  out  over  a  limited period of  time with  a 
limited number of patients it was not large enough to be of reasonable precision. 
All  the  available  modalities  of  treatment  were  not  assessed.  All  the  facts  and 
figures mentioned here may considerably vary from those of large series covering 
wide range of time, but still then, as the cases of this study were collected from a 
tertiary level hospital in our country, this study has some credentials in reflecting 
the  facts  regarding  factors  responsible  for  chronic  urticaria  and  the  available 
treatment options and the most favourable modality of treatment for patients. 
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SUMMARY 
 Chronic uritcaria, is a disease affecting 0.5 - 1 % of the population at any 
given time. It is a distressing disease encountered frequently in clinical practice. 
the current mainstay of therapy is the use of second-generation, non sedating anti-
histamines. However, in patients who do not respond satisfactorily to these agents, 
a variety of other drugs are used.
In  our  study  we  have  compared  the  efficacy  of  ASST,  Dapsone  and 
Methotrexate in the treatment of chronic urticaria. The following conclusions were 
reached.
Age and Sex Distribution :
Young females were the most commonly involved group. Twenty to thirty 
years  was  the  susceptible  age  group  along  with  female  gender.  This  is  in 
accordance with other Indian studies regarding the epidemiology of the disease.
Precipitating Factors :
One or other form of precipitating factor was present in more than half of all 
the patients involved in the study. The most commonly implicated precipitating 
factor in our study was food allergens followed by infections and inhalants. A study 
by  Godse  et  al  showed  that  infections  and  food  allergens  were  important 
precipitating factors in the Indian population.
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Atopy :
A basic tendency for allergic reactions, as indicated by the presence of atopic 
features was seen in twenty percent of all patients
Co - Morbid Factors :
 Our  study  showed  a  significant  level  of  prevalence  of  hypothyroidism 
among all treatment groups with bronchial asthma also widely prevalent. Both of 
these  are  considered  to  be  related  with  pathophysiological  process  of  chronic 
urticaria. Few people were diabetic or hypertensive, all of them belonging to the 
older age group and this had no significant correlation
Prevalence of ASST positivity :
Out of 120 patients in the study, 44 patients turned out to be positive for 
Autologous Serum Skin Test. Of these 37 patients were females and only 7 patients 
were males. This suggests that auto immunity may be the significant mechanism of 
chronic urticaria in our population. 
Comparison of the treatment groups :
In the ASST group, all patients had a significant reduction in their DLQI 
score with only two patients having poor response, which was explained by the 
fact that both those patients had a severe initial presentation. The response was 
especially good among those in whom the autologous serum skin test was positive. 
This response to ASST was found to be in concurrence with studies by Bajaj et al 
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and Staubach et al. Compliance was good and there was no evidence of relapse. 
The only factor which hinders with their use, especially in a government setup, is 
the technological expertise and the availability of centrifuge machines
In the Dapsone group, again there was a statistically significant improvement 
in response compared to the control group, but they compared unfavourably with 
ASST treatment group. The initial response was slower than that of ASST but the 
end point was similar especially in those responding well to treatment. There was 
good compliance, even though a couple of patients had minor side effects. These 
findings had concordance with studies conducted by Cooke et al, Engen et al and 
Boehm et al.
In the methotrexate group, there was a comparatively slower reduction in the 
DLQI score with response starting only near the end of treatment. They were better 
off than the control group but both the initial response and the end points were 
poor when compared to ASST. They had a comparable response to the patients 
treated with dapsone but its use is limited in patients with anaemia and deranged 
LFT. With the anaemia commonly prevalent in our population this limits its use in 
patients. Moreover, the incidence of side effects was more in this group. Studies by 
Sharma et al  advised the use of methotrexate in those with chronic recalcitrant 
urticaria who don't respond to other treatment modalities. 
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CONCLUSIONS 
On the basis of the findings of the study, the following recommendations can be 
made: 
1. Proper evaluation is mandatory to find out the presence of precipitating factor 
and if present, management of the same 
2. ASST can be considered as a first line of treatment, in patients with chronic 
urticaria, especially in those who are positive for Autologous Serum Skin Test. 
The preferred regimen being 2ml of autologous serum given as deep 
intramuscular injections once a week for nine weeks 
3. Dapsone can be considered for patients refractory to treatment. The regimen 
being 50mg daily for a period of 12 weeks. 
4. Methotrexate is recommended as last resort, in patients who are refractory to 
other modalities of treatment. Side effects profile and its contraindication in 
patients with haematological problems, restrict its more common usage 
5. A randomized, controlled study with prolonged follow up and involving much 
more modalities of treatment is necessary to devise an accepted management 
protocol for patients with chronic urticaria.
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APPENDIX  -  I   :    ETHICAL COMMITTEE CLEARANCE 
 
 110
Appendix-II 
DATA COLLECTION SHEET 
Name:     Age:   Sex:   
IP No. : 
ON ADMISSION: 
Main Complaints :  
Time of onset : 
Duration of urticaria : 
Duration of individual lesion : 
H/o Atopy : 
Family h/o autoimmune diseases : 
Co – Morbid Illness : 
Significant Past History : 
CLINICAL EXAMINATION: 
Pulse :      BP : 
RR :      Temp : 
Pallor :     Icterus : 
CVS  :      RS : 
P/A : 
Dermatological Examination  :   
• Morphology of lesion : 
• Distribution      : 
• Features of systemic involvement : 
• Evidence of infection  : 
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INVESTIGATIONS : 
CBC :      ESR : 
Liver Function Test  :   Renal Function Test : 
CXR : 
Autologous Serum Skin Test : 
TREATMENT : 
Group : 
Regimen given :  
FOLLOW UP  : 
Onset of remission : 
Duration of remission : 
Side effects :  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  DERMATOLOGY LIFE QUALITY INDEX 
              
Hospital No:     Date:       
Name:          Score: 
Address:     Diagnosis:      
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER 
THE LAST WEEK.  Please tick ➾ one box for each question. 
1. Over the last week, how itchy, sore,    Very much ❒ 
 painful or stinging has your skin      A lot  ❒ 
 been?         A little  ❒ 
         Not at all ❒ 
2. Over the last week, how embarrassed   Very much ❒ 
 or self conscious have you been because    A lot  ❒ 
 of your skin?        A little  ❒ 
         Not at all ❒ 
3. Over the last week, how much has your    Very much ❒ 
 skin interfered with you going     A lot  ❒ 
 shopping or looking after your home or    A little  ❒ 
 garden?              Not at all ❒ Not relevant ❒ 
4. Over the last week, how much has your    Very much ❒ 
 skin influenced the clothes      A lot  ❒ 
 you wear?       A little  ❒ 
         Not at all ❒ Not relevant ❒ 
5. Over the last week, how much has your    Very much ❒ 
 skin affected any social or      A lot  ❒ 
 leisure activities?      A little  ❒ 
         Not at all ❒ Not relevant ❒ 
6. Over the last week, how much has your    Very much ❒ 
 skin made it difficult for      A lot  ❒ 
 you to do any sport?      A little  ❒ 
         Not at all ❒ Not relevant ❒ 
7. Over the last week, has your skin prevented  Yes  ❒ 
 you from working or studying?    No  ❒ Not relevant ❒ 
  
 If "No", over the last week how much has    A lot  ❒ 
 your skin been a problem at                 A little  ❒ 
 work or studying?      Not at all ❒ 
8. Over the last week, how much has your    Very much ❒ 
 skin created problems with your     A lot  ❒ 
 partner or any of your close friends              A little  ❒ 
 or relatives?        Not at all ❒ Not relevant ❒ 
9. Over the last week, how much has your    Very much ❒ 
 skin caused any sexual      A lot  ❒ 
 difficulties?       A little  ❒ 
         Not at all ❒ Not relevant ❒ 
10. Over the last week, how much of a               Very much ❒ 
 problem has the treatment for your              A lot  ❒ 
 skin been, for example by making    A little  ❒ 
 your home messy, or by taking up time?    Not at all ❒ Not relevant ❒ 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DLQI Score : The scoring of each question is as follows: 
Very much scored 3 
A lot  scored 2 
A little scored 1 
Not at all/ Not relevant/ Question unanswered scored 0 
Question 7: "prevented work or studying" scored 3 
UAS (Urticaria Activity Score)  : 
Score Wheal Pruritis
0 None None
1 Mild (<20 wheals/24h) Mild
2 Moderate (20-50 wheals/24h) Troublesome but doesn’t interfere with sleep
3 Severe (>50 wheals/24h or large confluent 
areas of wheals)
Severe, interferes with normal activity and sleep
UAS SCORE DLQI SCORE
Start of Treatment
End of Treatment
6 months following treatment
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INFORMATION SHEET 
TITLE :  “A Comparative Study On The Efficacy Of Methotrexate Vs Dapsone Vs 
ASST (Autologous Serum Skin Therapy) For Treatment Of Chronic Urticaria” 
Name of Investigator : Dr. Meenakshi M.  Name of Participant : 
Purpose of Research : The purpose of the study is to compare the efficacy of the various 
modalities of treatment like methotrexate, dapsone and ASST (Autologous Serum Skin 
Therapy) for treatment of chronic urticarial. 
Study Design  : Prospective Observational Study 
Study Procedures : Patient will be subjected to routine investigations, Autologous 
Serum Skin Test & Chest X ray. The patients are then randomly grouped into 4 groups 
and undergo treatment. 
Possible Risks : No risks to the patient 
Possible benefits 
To patient : Patient is provided an alternative modality of treatment which will help in 
remission of their disease. 
To doctor & to other people :  If this study gives positive results, it can help determine 
the most effective treatment and the treatment protocol for patients with chronic urticaria. 
This will help in providing better and complete treatment to other patients in future. 
Confidentiality of the information obtained from you : The privacy of the patients in 
the research will be maintained throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable information will be 
shared 
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Can you decide to stop participating in the study : Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to withdraw at any 
time 
How will your decision to not participate in the study affect you : Your decision will 
not result in any loss of benefits to which you are otherwise entitled. 
Signature of Investigator                Signature of  Participant 
Date : 
Place : 
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ஆராyc& தகவl தாll
ஆராyc+ எ- : உll ேநாயா2 எ-   : 
பŋேக5பாள78 ெபயr : வய;  :           ஆ- / ெப- :
ெச8ைன ரா?v காnB அரD ெபா; மFt;வமைனHl DைணtதJpL ேநாH5M 
டாpேசா8 (Dapsone), OேதாBெரksெசR (Methotrexate) ம5Sm எ.எs.எs.J (ASST) 
ேபா8ற ைவBயŋக28 பயVைடைம ப5W அWவத5கான ஆராyc+ நைடெபற உllள;. 
இnத ஆராyc+Hl தாŋகll பŋM ெ பற நாŋகll YFmLZேறாm. இnத ஆராyc+Hl 
தŋக[kM இரtத ப7ேசாதைன ெ சyயpபR\ π8L தŋக[kM Zைடkக ே வ-Jய 
ைவtBயm, ஆராyc+H8 ேதைவH8 ேப7l அ2kக ப\m.. 
இnத ஆராyc+H8 ^லm தŋக28 +Zcைச எvYதtB`m பாBpபைடயா;. இnத 
ஆராyc+H8 µJbகll ேநrமைற µJbகளாக இFpπ8 அ; π8 வFm ேநாயா2க[kM 
பயVllளதாகbm இFkMm. 
இnத ஆராyc+Hனாl தŋக28 ேநாH8 ஆyவWkைகேயா அlல; +Zcைசேயா 
பாBpL அைடயா; எ8S ெ த7Yt; ெகாllZேறாm. µJbகைள அlல; கFt;கைள 
ெவ2H\mேபாேதா அlல; ஆராyc+H8 ேபாேதா தŋகள; ெ பயைரேயா அlல; 
அைடயாளŋகைளேயா ெவ2Hட மாRேடாm எ8பைதcm ெத7Yt; ெகாllZேறாm. 
இnத ஆராyc+Hl பŋேக5ப; தŋகள; YFpபtB8 ேப7l மR\m தா8. ேம`m 
இnத ஆராyc+H8 µJbகll தŋக[kM அWYkகpப\m எ8Sm ெ த7Yt; 
ெகாllZேறாm. ே ம`m dŋகll எnேநரµm இnத ஆராyc+HeFn; π8வாŋகலாm 
எ8பைதcm ெத7Yt; ெகாllZேறாm. 
ஆராyc+யாளr  ைகெயாpபm பŋேக5பாளr ைகெயாpபm  
நாll   :
இடm  :
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PATIENT CONSENT FORM 
Patient may check (☑) these boxes 
Signature/thumb impression 
Patient’s Name and Address:  
Signature of Investigator 
Study Investigator’s Name: 
Dr. MEENAKSHI M., 
Study Detail : “ A C O M PA R AT I V E S T U D Y O N T H E 
EFFICACY OF METHOTREXATE VS DAPSONE VS 
ASST (AUTOLOGOUS SERUM SKIN THERAPY) 
FOR TREATMENT OF CHRONIC URTICARIA”
Study Centre : Rajiv Gandhi Government General Hospital, Chennai.
Patient’s Name :
Patient’s Age :
In Patient Number :
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity to 
ask question and all my questions and doubts have been answered to my complete satisfaction. ❏
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. ❏
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be conducted in relation to it, even 
if I withdraw from the study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. ❏
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual symptoms. ❏
I hereby consent to participate in this study ❏ 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests and to undergo treatment ❏
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ஆராyc+ ஒpLதl பJவm
ஆராyc+H8 தைலpL : DைணtதJpL ேநாH5M டாpேசா8 (Dapsone) , 
OேதாBெரksெசR (Methotrexate) ம5Sm எ.எs.எs.J (ASST) ேபா8ற ைவBயŋக28 
பயVைடைம ப5W அWவத5கான ஆராyc+
பŋMெகாllவ78 ெபயr : 
ஆராyc+ ெசyபவ78 ெபயr :  OனாR+ O.
இடm : ரா?v காnB அரD ெபா; மFt;வமைன, ெச8ைன – 600003 
 __________________________________  எVm நா8, எனkM ெகா\t;llள தகவl 
தாைள பJt; L7n; ெகா-ேட8. நா8 பBெனR\ வயைத கடn;llளதாl, எ8Vைடய 
DயgைனbடVm, µh DகnBர;டVm, இnத ஆராyc+Hl எ8ைன ே சrt;kெகாllள 
சmமBkZேற8. 
நா8, எனkM ெகா\t;llள தகவl தாைள பJt; L7n; ெகா-ேட8. 
எனkM இnத ஆராyc+H8 ஒpLதl பJவm Yளkக பR\llள;. 
எனkM இnத ஆராyc+H8 ேநாkகµm, Yவரŋக[m YளkகpபRட;. 
எனkM எ8Vைடய உ7ைமகll ப5W YளkகpபRட;. 
இnத ஆராyc+Hl இFn; நா8 எ8 ேநரµm π8 வாŋகலாm எ8Sm, அதனாl எnத π8 
Yைளbm ஏ5படா; எ8S L7n; ெகா-ேட8. 
எ8ைன ப5W எnத தகவ`m, அைடயாளŋக[m ெவ2Hடpபட மாRட; எ8பைதcm L7n; 
ெகா-ேட8. 
எ8Vைடய µh DகnBர;டVm இnத ஆராyc+Hl ேசrt; ெகாllள சmமBkZேற8.  
பŋேக5பாளr ைகெயாpபm      ஆராyc+யாளr ைகெயாpபm
நாll : 
இடm : 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                 Appendix-IV: Plagiarism  
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APPENDIX V   :   MASTERCHART  
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 124
  125
  126
KEY : 
DM - - Diabetes Mellitus 
HTN - - Hypertension 
Hypothy - - Hypothyroidism 
DG - - Dermographism 
An - - Anemia 
Es - - Esonophilia 
ASST - - Autologous serum skin test/therapy 
UAS - - Urticarial Activity Score 
DLQI - - Dermatological Life Quality Index
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